Reducing forward lipoprotientransport from the liver to the periphery (VLDL/IDL/LDL/ApoB) and increasing reverse(HDL/ApoA1) lipoprotein transport (from the periphery to the liver) could reduce the influence of dyslipidaemia on the membrane lipids and function of T-cells and B-cells and improve the efficacy of current disease specific therapeutics and of those currently in clinical trials. This evidence concerns the gene APOB and inherited lipid metabolism disorder.